These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30033395)

  • 21. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactose engineering for better performance in dry powder inhalers.
    Rahimpour Y; Hamishehkar H
    Adv Pharm Bull; 2012; 2(2):183-7. PubMed ID: 24312791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler.
    Yeung S; Traini D; Tweedie A; Lewis D; Church T; Young PM
    J Pharm Sci; 2019 Feb; 108(2):949-959. PubMed ID: 30312722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of Dry Powders to the Lungs: Influence of Particle Attributes from a Biological and Technological Point of View.
    Zellnitz S; Roblegg E; Pinto J; Fröhlich E
    Curr Drug Deliv; 2019; 16(3):180-194. PubMed ID: 30360739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methods for reduction of cohesive forces between carrier and drug in DPI formulation.
    Desai SS; Aher AA; Kadaskar PT
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1589-98. PubMed ID: 23050727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation techniques for high dose dry powders.
    Brunaugh AD; Smyth HDC
    Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
    Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
    Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dry powder inhaler formulation.
    Telko MJ; Hickey AJ
    Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering the right formulation for enhanced drug delivery.
    Ke WR; Chang RYK; Chan HK
    Adv Drug Deliv Rev; 2022 Dec; 191():114561. PubMed ID: 36191861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formulation Design of Dry Powders for Inhalation.
    Weers JG; Miller DP
    J Pharm Sci; 2015 Oct; 104(10):3259-88. PubMed ID: 26296055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dry powder inhalable formulations for anti-tubercular therapy.
    Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery--a review for multidisciplinary researchers.
    Islam N; Cleary MJ
    Med Eng Phys; 2012 May; 34(4):409-27. PubMed ID: 22277307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.